Meningococcal Vaccine (review)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SOBOUTI BEHNAM; FALLAH SHAHRZAD

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF CLINICAL EXCELLENCE Year:2018 | Volume:8 | Issue:1 Page(s): 7-8

Download Full-Text

Persian Verion

View:

1,980

Download:

Cites:

Information Journal Paper

Title

Meningococcal Vaccine (review)

Author(s)

SOBOUTI BEHNAM | FALLAH SHAHRZAD | Issue Writer Certificate

Keywords

VaccineQ2

MeningococcalQ2

Neisseria meningitidisQ2

Abstract

Neisseria meningitidis has 13 clinically significant serogroups, classified according to the antigenic structure of their polysaccharide capsule. Six serogroups, A, B, C, Y, W-135, and X, are responsible for virtually all cases of the disease in humans. Quadrivalent (Serogroups A, C, W-135, and Y) There are currently three Vaccines available in the US to prevent Meningococcal disease, all quadrivalent in nature, targeting serogroups A, C, W-135, and Y: Two conjugate Vaccines (MCV-4), Menactra and Menveo, and One polysaccharide Vaccine (MPSV-4), Menomune, produced by Sanofi Pasteur. Bivalent (Serogroups C and Y): On 2012, the FDA approved a new combination Vaccine against two types of Meningococcal disease and Hib disease for infants and children 6 weeks to 18 months old. The Vaccine, Menhibrix, will prevent disease caused byNeisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. This is the first Meningococcal Vaccine that can be given to infants as young as six weeks old. Serogroup A: A Vaccine called MenAfriVac has been developed through a program called the Meningitis Vaccine Project and has the potential to prevent outbreaks of group A meningitis. Serogroup B: Vaccines against serotype B Meningococcal disease have proved difficult to produce, and require a different approach from Vaccines against other serotypes. Serogroup X: The occurrence of serogroup X has been reported in North America, Europe, Australia, and West Africa. Current meningoccocal meningitis Vaccines are not known to protect against serogroup X N. meningitidis disease. Side effects of the Vaccine include: Common side effects include pain and redness around the site of injection (up to 50% of recipients). A small percentage of people develop a mild fever. As with any medication, a small proportion of people develop a severe allergic reaction. The highest risk was when individuals received a dose of Soliris within 2 weeks after being vaccinated with Bexsero.

Cites

No record.

References

No record.

Cite

APA: Copy

SOBOUTI, BEHNAM, & FALLAH, SHAHRZAD. (2018). Meningococcal Vaccine (review). JOURNAL OF CLINICAL EXCELLENCE, 8(1 ), 7-8. SID. https://sid.ir/paper/391642/en

Vancouver: Copy

SOBOUTI BEHNAM, FALLAH SHAHRZAD. Meningococcal Vaccine (review). JOURNAL OF CLINICAL EXCELLENCE[Internet]. 2018;8(1 ):7-8. Available from: https://sid.ir/paper/391642/en

IEEE: Copy

BEHNAM SOBOUTI, and SHAHRZAD FALLAH, “Meningococcal Vaccine (review),” JOURNAL OF CLINICAL EXCELLENCE, vol. 8, no. 1 , pp. 7–8, 2018, [Online]. Available: https://sid.ir/paper/391642/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops